Short answer
Janux Therapeutics, Inc. (JANX) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 88.2% of outstanding shares represented at the June 11 annual meeting, supporting strong shareholder participation.
Janux Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 88.2% of outstanding shares represented at the June 11 annual meeting, supporting strong shareholder participation
- Natasha Hernday and Eric Dobmeier elected as Class II directors through the 2029 annual meeting
- Eric Dobmeier received 46,279,387 votes for versus 1,090,512 withheld, indicating stronger shareholder support
- Ernst & Young ratified as independent auditor for fiscal year ending December 31, 2026, with 53,560,969 votes for
- Executive compensation approved advisory basis, with 42,749,182 votes for versus 4,574,376 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Janux Therapeutics, Inc. 8-K filings
Get the next JANX 8-K as it lands
Follow JANX for push alerts, or ask the research agent what this filing means.